A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults
- Resource Type
- Article
- Source
- In
Vaccine 13 June 2023 41(26):3898-3906 - Subject
- Language
- ISSN
- 0264-410X